Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Merck & Co., Inc. (MRK): Don’t Invest in Biotech IPOs Until You Read This

Page 1 of 2

A spate of 10 biotechs went public this year, raising over $725 million. As one banker put it, this is a sector “where investors take binary risks, and investor willingness to take on additional risk is picking up.” However, IPO investment is risky business, and one needs to consider who makes the most money – the company, the investor or some third party who buys up a struggling IPO.

A changing scene

A classic example is that of the 2011 acquisition of Inspire by Merck & Co., Inc. (NYSE:MRK)$430 million was considered a great offer – at $5 a share, it represented a 26% premium to Inspire’s share price at that time. However, it did not cover the amount spent by Inspire to develop its pipeline.

Merck & Co., Inc.Credit: Merck & Co., Inc. (NYSE:MRK)

In 2010 and 2011, the biotech IPO market was almost dead. Plexxikon, a drug discovery company, was forced to sell itself to Japan’s Daiichi Sankyo after the former’s IPO did not evince any investor interest, although it had an impressive candidate for treatment of melanoma and a strong management team.

But there is renewed investor interest in small biotech companies now. One reason is that last year, the FDA approved the highest number of drugs (39) in over a decade. Another possible reason could be that year to date, the NASDAQ Biotechnology index has outperformed the sluggish S&P 500.

The most recent IPO announcement comes from Agios Pharmaceuticals, going up for $86 million. Earlier there were Epizyme Inc (NASDAQ:EPZM), Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), and Enanta Pharmaceuticals Inc (NASDAQ:ENTA), which all went public and started trading earlier this year.

A risky gamble

Five of the ten IPOs this year are trading above their offer prices. In June first week, Epizyme Inc (NASDAQ:EPZM), with two candidates in clinical trials, went public at $15 a share. The stock touched $30.86 in a single day, and now trades at $23.82.

However, regardless of the decent returns from biotech IPOs in 2013, generally IPOs are not good for your portfolio — at least not for the first year of their trading. BusinessWeek studied 25 of the biggest IPOs of 2010 and 2011 with the biggest opening trading pops. It found (at that time) that 20 of them had fallen since then and were trading below their opening price – many had fallen 50%.

Biotech is no exception to the rule. Only about 50% of the biotech IPOs of 2011 are up since their debuts, which is not exactly an optimistic investing scenario.

Some lesser-known facts

Small biotech companies excel at discovering and developing new drugs, while Big Pharma tries to acquire them as those drugs progress towards FDA approvals. However, these small biotech companies spend far too much money on drugs that seldom get to the market. When a big biotech acquires such a smaller one, you need to see whether the premium price it’s offered covers the smaller company’s cost of product development.

Consider Adolor’s takeover in 2011 by Cubist Pharmaceuticals Inc (NASDAQ:CBST). At a premium of 143%, it appeared good; however, it was actually a bad deal for investors, because Adolor was getting only $221 million against the $530 million it had spent developing its product portfolio.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!